ペットワクチン市場- 世界の産業規模、シェア、動向、機会、予測、動物の種類別、ワクチン接種別、投与方法別、地域別、競合別、2020～2030年

ペットワクチンの世界市場規模は2024年に113億1,000万米ドルとなり、予測期間には161億米ドルに達すると予測され、2030年までのCAGRは6.04%です。

世界のペットワクチン市場は、ペット飼育の増加と動物の健康に対する意識の高まりにより、大きな成長を遂げています。ペットの飼育数が増え続ける中、動物を感染症から守るためにワクチン接種を含む予防ヘルスケアが重視されるようになっています。獣医医療の進歩により、より効果的なワクチンが開発され、狂犬病、ジステンパー、パルボウイルスなどの病気に対する予防効果が高まっています。獣医療サービスの利用可能性が拡大し、診療所や病院、オンラインプラットフォームを通じてペット用ワクチンへのアクセスが向上していることも、市場拡大にさらに寄与しています。各メーカーは、有効性が強化され、予防期間が長くなった次世代ワクチンを導入するため、研究開発に投資しています。

バイオテクノロジーの革新とDNAワクチンや組み換えワクチンの台頭により、市場の様相は一変しています。各社は、1回の接種で複数の疾患に対する免疫を獲得できる混合ワクチンの開発に注力しており、動物病院を受診する頻度を減らし、ペットのコンプライアンスを向上させています。コンパニオンアニマルワクチン、特にイヌとネコに対する需要の高まりが市場の成長を促進しています。動物のワクチン接種プログラムを推進する政府の取り組みや、予防接種を義務付ける厳しい規制が市場力学を強化しています。ワクチン接種費用を含むペット保険の適用範囲が拡大していることが、ペットの飼い主に予防ヘルスケアへの投資を促しています。可処分所得の増加や、飼い主が動物を家族の一員として扱うというペットの人間化も、ペット用ワクチンの需要拡大に寄与しています。

主な市場促進要因

コンパニオンアニマルにおける疾病の有病率の増加

主な市場課題

ワクチン接種の高コスト

主な市場動向

個別化されたペット用ワクチンに対する需要の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のペットワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 動物の種類別（犬、猫、馬）
  • ワクチン接種別（犬科、猫科、その他）
  • 投与方法別（注射ワクチン、鼻腔内ワクチン）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のペットワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のペットワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のペットワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のペットワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのペットワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Bayer AG
• Elanco US Inc.
• Merck KGaA
• Merial Inc.
• Virbac SA
• Zoetis Inc
• Phibro Animal Health Corporation
• Boehringer Ingelheim GmbH
• Tianjin Ringpu Bio-Technology Co., Ltd
• Vetoquinol SA

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Pet Vaccine Market was valued at USD 11.31 Billion in 2024 and is expected to reach USD 16.10 Billion in the forecast period with a CAGR of 6.04% through 2030. The global pet vaccine market is experiencing significant growth, driven by increasing pet adoption and rising awareness about animal health. As pet ownership continues to rise, there is a growing emphasis on preventive healthcare, including vaccination, to protect animals from infectious diseases. Veterinary healthcare advancements have led to the development of more effective vaccines, ensuring better protection against diseases such as rabies, distemper, and parvovirus. The expanding availability of veterinary services and improved access to pet vaccines through clinics, hospitals, and online platforms are further contributing to market expansion. Manufacturers are investing in research and development to introduce next-generation vaccines with enhanced efficacy and longer protection duration.

Innovations in biotechnology and the rise of DNA and recombinant vaccines are transforming the market landscape. Companies are focusing on developing combination vaccines that provide immunity against multiple diseases with a single shot, reducing the frequency of veterinary visits and improving pet compliance. The rising demand for companion animal vaccines, particularly for dogs and cats, is fueling market growth. Government initiatives promoting animal vaccination programs and stringent regulations mandating immunization are strengthening market dynamics. The expansion of pet insurance coverage, which increasingly includes vaccination costs, is encouraging pet owners to invest in preventive healthcare. Increasing disposable income and the humanization of pets, where owners treat animals as family members, are also contributing to the growing demand for pet vaccines.

Key Market Drivers

Increasing Prevalence of Diseases in Companion Animals

The increasing prevalence of diseases in companion animals is a significant driver of the global pet vaccine market. In 2023, the World Health Organization (WHO) reported that rabies causes an estimated 59,000 human deaths annually, with dogs responsible for 99% of these transmissions. This alarming statistic underscores the critical need for effective vaccination programs to control rabies in canine populations, thereby protecting both animal and human health. Similarly, the WHO has highlighted concerns about psittacosis, a zoonotic disease transmitted from birds to humans. In February 2024, several European countries, including Austria, Denmark, Germany, Sweden, and the Netherlands, reported an increase in psittacosis cases observed in 2023 and early 2024, particularly since November-December 2023. These instances exemplify the rising incidence of zoonotic diseases, emphasizing the necessity for comprehensive vaccination strategies in companion animals.

Veterinary professionals and regulatory bodies are actively promoting routine vaccination schedules to curb the spread of these highly contagious diseases among pets. Government-led initiatives and vaccination mandates in several countries are reinforcing immunization practices, ensuring broader coverage among companion animals. For instance, the WHO recommends that vaccinating at least 70% of dogs in areas at risk is the most effective way of preventing human rabies deaths. This strategy not only safeguards animal health but also significantly reduces the risk of zoonotic disease transmission to humans. The increasing urbanization and closer human-animal interactions have raised concerns about zoonotic disease transmission, prompting pet owners to prioritize vaccinations as a preventive measure. In densely populated areas, the risk of disease outbreaks among pets is higher, making immunization an essential part of pet healthcare.

The increasing number of pet owners worldwide has been a driving force behind the expansion of veterinary healthcare facilities. For example, in countries such as the United States, over 90 million households now own pets, which has created a larger market for pet healthcare services. This surge in pet ownership has prompted veterinary clinics to expand their operations and offer more comprehensive healthcare solutions. At the same time, advancements in veterinary care, such as improved diagnostic tools and treatment options, have made it easier for clinics to provide effective care, including timely vaccinations for pets.

Government initiatives also play a crucial role in supporting the growth of veterinary healthcare infrastructure. Several countries have implemented programs to promote animal health and strengthen the veterinary workforce, including funding for veterinary clinics and training for veterinary professionals. This, in turn, ensures greater access to vaccines for pets and contributes to higher vaccination rates. As more pet owners seek professional care for their animals, the demand for dog vaccines continues to rise, further fueling the market's growth. Improved infrastructure and government support are creating a favorable environment for increased pet vaccination, thereby driving the expansion of the pet vaccine market.

Key Market Challenges

High Cost of Vaccination

One of the major challenges facing the global pet vaccine market is the high cost of vaccination, which can limit access to essential preventive healthcare for pets, particularly in lower-income regions. The price of vaccines varies depending on the type of vaccine, the brand, and the country in which they are administered. Vaccination costs are influenced by several factors, including the research and development expenses involved in creating new vaccines, regulatory fees, and distribution costs. For example, combination vaccines, which provide protection against multiple diseases in one dose, can be more expensive than single vaccines, further escalating the overall cost for pet owners.

In addition to the direct costs of vaccines, pet owners may incur additional charges for veterinary consultations and health assessments to determine which vaccines are needed for their dogs. This makes the vaccination process financially challenging for individuals, especially in regions where veterinary care is not subsidized or where pet healthcare is not covered by insurance. According to a report from the American Kennel Club, a basic vaccination package for a dog in the U.S. can cost anywhere from USD 75 to USD 150, depending on the vaccines included. More advanced vaccines or those for rare diseases may cost even more. These costs can be a significant burden for pet owners in developing countries or low-income households, potentially resulting in lower vaccination rates.

Key Market Trends

Increasing Demand for Personalized Pet Vaccines

The increasing demand for personalized pet vaccines represents a notable trend in the Pet Vaccine Market. This trend reflects a growing recognition that not all pets are alike, and tailoring vaccines to an individual animal's specific needs can yield significant benefits. Personalized pet vaccines involve customizing vaccination schedules and formulations based on factors such as a pet's age, breed, lifestyle, and geographic location. This approach ensures that each pet receives the most appropriate and effective protection against diseases, optimizing their overall health and minimizing unnecessary vaccinations. Advances in veterinary diagnostics, including genetic testing and serological assays, allow for a more precise understanding of a pet's immune status and susceptibility to specific diseases. This information can inform personalized vaccine recommendations. Pet owners increasingly view their pets as members of the family and are willing to invest in their well-being. They seek out veterinary practices that offer tailored healthcare plans, including personalized vaccines, to ensure the best outcomes for their pets.

Concerns about over-vaccination have led to a more selective approach to vaccinations. Personalization allows veterinarians to minimize unnecessary vaccinations, reducing the potential for adverse reactions and vaccine-related health issues. Regional disease prevalence varies, and some areas may have specific disease risks. Personalized vaccines can address these geographical variations, providing pets with targeted protection. In summary, the demand for personalized pet vaccines is driven by a shift toward individualized pet care and a desire to optimize vaccine effectiveness while minimizing risks. This trend aligns with the broader movement toward personalized medicine and is likely to continue shaping the Pet Vaccine Market in the coming years.

Key Market Players

• Bayer AG
• Elanco US Inc.
• Merck KGaA
• Merial Inc.
• Virbac SA
• Zoetis Inc
• Phibro Animal Health Corporation
• Boehringer Ingelheim GmbH
• Tianjin Ringpu Bio-Technology Co., Ltd
• Vetoquinol SA

Report Scope:

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Vaccine Market, By Animal Type:

• Canine
• Feline
• Equine

Pet Vaccine Market, By Vaccination:

• Canine Family
• Feline Family
• Others

Pet Vaccine Market, By Mode Of Administration:

• Injectable Vaccines
• Intranasal Vaccines

Pet Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Pet Vaccine Market.

Available Customizations:

Global Pet Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Pet Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Canine, Feline, Equine)
  • 5.2.2. By Vaccination (Canine Family, Feline Family, Others)
  • 5.2.3. By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Pet Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Vaccination
  • 6.2.3. By Mode Of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pet Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Vaccination
      • 6.3.1.2.3. By Mode Of Administration
  • 6.3.2. Mexico Pet Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Vaccination
      • 6.3.2.2.3. By Mode Of Administration
  • 6.3.3. Canada Pet Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Vaccination
      • 6.3.3.2.3. By Mode Of Administration

7. Europe Pet Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Vaccination
  • 7.2.3. By Mode Of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pet Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Vaccination
      • 7.3.1.2.3. By Mode Of Administration
  • 7.3.2. Germany Pet Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Vaccination
      • 7.3.2.2.3. By Mode Of Administration
  • 7.3.3. United Kingdom Pet Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Vaccination
      • 7.3.3.2.3. By Mode Of Administration
  • 7.3.4. Italy Pet Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Vaccination
      • 7.3.4.2.3. By Mode Of Administration
  • 7.3.5. Spain Pet Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Vaccination
      • 7.3.5.2.3. By Mode Of Administration

8. Asia-Pacific Pet Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Vaccination
  • 8.2.3. By Mode Of Administration
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pet Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Vaccination
      • 8.3.1.2.3. By Mode Of Administration
  • 8.3.2. India Pet Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Vaccination
      • 8.3.2.2.3. By Mode Of Administration
  • 8.3.3. South Korea Pet Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Vaccination
      • 8.3.3.2.3. By Mode Of Administration
  • 8.3.4. Japan Pet Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Vaccination
      • 8.3.4.2.3. By Mode Of Administration
  • 8.3.5. Australia Pet Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Vaccination
      • 8.3.5.2.3. By Mode Of Administration

9. South America Pet Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Vaccination
  • 9.2.3. By Mode Of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pet Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Vaccination
      • 9.3.1.2.3. By Mode Of Administration
  • 9.3.2. Argentina Pet Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Vaccination
      • 9.3.2.2.3. By Mode Of Administration
  • 9.3.3. Colombia Pet Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Vaccination
      • 9.3.3.2.3. By Mode Of Administration

10. Middle East and Africa Pet Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Vaccination
  • 10.2.3. By Mode Of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pet Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Vaccination
      • 10.3.1.2.3. By Mode Of Administration
  • 10.3.2. Saudi Arabia Pet Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Vaccination
      • 10.3.2.2.3. By Mode Of Administration
  • 10.3.3. UAE Pet Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Vaccination
      • 10.3.3.2.3. By Mode Of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Bayer AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Elanco US Inc.
• 14.3. Merck KGaA
• 14.4. Merial Inc.
• 14.5. Virbac SA
• 14.6. Zoetis Inc
• 14.7. Phibro Animal Health Corporation
• 14.8. Boehringer Ingelheim GmbH
• 14.9. Tianjin Ringpu Bio-Technology Co., Ltd
• 14.10. Vetoquinol SA

15. Strategic Recommendations

16. About Us & Disclaimer